Cargando…

ODP605 Body Mass Index and Weight Reductions in Patients With SRC1 Genetic Variant Obesity After 1 Year of Setmelanotide

BACKGROUND: The melanocortin-4 receptor (MC4R) pathway is a key regulator of energy balance. Steroid receptor coactivator 1 (SRC1; also known as NCOA1) is a transcriptional coactivator that regulates proopiomelanocortin (POMC) expression in the MC4R pathway. Certain SRC1 variants impair MC4R signali...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martos-Moreno, Gabriel Á, Argente, Jesús, Scimia, Cecilia, Ohayan, Olga, Yuan, Guojun, Farooqi, Sadaf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Adipose Tissue, Appetite, & Obesity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624833/ http://dx.doi.org/10.1210/jendso/bvac150.028

Ejemplares similares

OR10-1 Body Mass Index and Weight Reductions in Patients With Obesity Due to Heterozygous Variants in POMC, PCSK1, and LEPR After 1 Year of Setmelanotide
por: Farooqi, Sadaf, et al.
Publicado: (2022)

RF24 | PSUN96 Setmelanotide in Patients With Heterozygous POMC, LEPR, SRC1, or SH2B1 Obesity: Design of EMANATE – A Placebo-Controlled Phase 3 Trial
por: Wabitsch, Martin, et al.
Publicado: (2022)

ODP607 Long-term Efficacy of Setmelanotide in Patients With POMC or LEPR Deficiency Obesity
por: Clément, Karine, et al.
Publicado: (2022)

RF24 | PSUN91 Body Mass Index and Weight Reduction in Patients With SH2B1 Genetic Variant Obesity After One Year of Setmelanotide
por: Argente, Jesús, et al.
Publicado: (2022)

ODP606 Long-term Efficacy of Setmelanotide in Patients With Bardet-Biedl Syndrome
por: Argente, Jesús, et al.
Publicado: (2022)

SAT656 Weight Reduction After 6 Months Of Setmelanotide Treatment In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)

FRI082 Impact Of Setmelanotide On Metabolic Parameters And Vital Signs In Patients With Hypothalamic Obesity
por: Jennifer Abuzzahab, M, et al.
Publicado: (2023)

FRI066 Treatment History And Comorbidities Reported By Patients With Hypothalamic Obesity Treated With Setmelanotide In A Phase 2 Trial
por: Roth, Christian L, et al.
Publicado: (2023)

FRI065 Trial Design Of A Double-blind, Randomized, Placebo-controlled, Phase 3 Study Of Setmelanotide In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)

A Phase 3 Trial in Participants With Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide
por: Haws, Robert, et al.
Publicado: (2021)

Timing of Onset of Adverse Events With Setmelanotide, an MC4R Agonist, in Patients With Severe Obesity Due to LEPR or POMC Deficiency
por: Clément, Karine, et al.
Publicado: (2021)

SAT-605 Characterization of Dual Projection Patterns of Refeeding-Activated Neurons in the Parasubthalamic Nucleus
por: Wittmann, Gabor, et al.
Publicado: (2020)

SUN-605 Mediastino-Abdominal Lipomatosis: Deep Accumulation of Fat Mimicking a Respiratory Disease
por: Correa, Ricardo Rafael, et al.
Publicado: (2020)

MON-LB019 Setmelanotide (RM-493) Reduces Food Intake and Rapidly Induces Weight Loss in a Mouse Model of Alström Syndrome
por: Stephenson, Erin, et al.
Publicado: (2019)

MON-605 Serum CD163, but Not Gal-3, Predicts Response to Liraglutide Therapy in Obese Patients
por: Mat, Arimin, et al.
Publicado: (2020)

ODP001 AKR1C2 Activity in Abdominal Adipose Tissue of Women with or without Excess Visceral Adiposity
por: Ostinelli, Giada, et al.
Publicado: (2022)

ODP003 Different Phenotypes of Obesity: Focus on The Intestinal Microbiom and The Adipomyokin Profile
por: Volkova, Natalya, et al.
Publicado: (2022)

ODP010 Relaxin Receptor RXFP1 Knockout in Adipose Tissue Progenitor Cells Results in Resistance to High Fat Diet-Induced Weigh Gain
por: Bennett, Robert, et al.
Publicado: (2022)

ODP002 ASSOCIATION BETWEEN OBESITY AND DIABETES POTENTIATES RENAL FUNCTION IMPAIRMENT IN BARIATRIC PATIENTS
por: Naliato, Erika
Publicado: (2022)

ODP009 Obesity-related Conditions in Adults with Overweight and Obesity in the United States: A Cluster Analysis
por: Chiu, Kevin, et al.
Publicado: (2022)

ODP008 Nonalcoholic Fatty Liver Disease (NAFLD) Impacts Weight Loss after Bariatric Surgery
por: Abu-Rumaileh, Mohammed, et al.
Publicado: (2022)

ODP591 Obesity and Weight Loss Apps in COVID-19 Era: Do They Help Both the Doctor and the Patient?
por: Lawrence, Rebecca, et al.
Publicado: (2022)

ODP005 Molecular Characterization of Early Adipose Tissue Remodeling and Fibrosis in a Murine Model of Diet-Induced Obesity.
por: Timms, Katie, et al.
Publicado: (2022)

ODP014 Safety and Efficacy of IBI362 (LY3305677) 9 mg and 10 mg in Chinese Adults with Overweight or Obesity
por: Ji, Linong, et al.
Publicado: (2022)

ODP006 Multidisciplinary Weight Management Improves Body Weight And Body Mass Composition In Breast Cancer Women Undergoing Adjuvant Chemotherapy
por: Nguyen, Vivien, et al.
Publicado: (2022)

SUN-LB016 The Long Term Effects of Resveratrol Supplementation during Pregnancy and Lactation on Adipose Tissue Morphology in the Adult Offspring
por: Ros-Pérez, Purificación, et al.
Publicado: (2019)

ODP007 Nephron Specific ATP6AP2 Knockout Increases Urinary Excretion of Fatty Acids while Decreasing Renal Cortical Megalin Expression
por: Culver, Silas, et al.
Publicado: (2022)

ODP011 Single Nuclei RNA-Sequencing of Frozen Human Adipose Tissue and PET/CT Imaging Coupled With Deep-Learning Reveals Single-Cell Landscape and Transcriptional Dynamics Related to Adipocyte Hypertrophy and in Vivo Dysmetabolism
por: Ye, Run Zhou, et al.
Publicado: (2022)

ODP004 Glucose Profiles and Insulin Sensitivity in Adults with Overweight/Obesity Participating in a Weight Loss Intervention based on Early Time-Restricted Eating plus Daily Caloric Restriction vs Daily Caloric Restriction Alone
por: Jeffers, Rebecca, et al.
Publicado: (2022)

SAT660 Predictors Of Achieving Body Weight Reduction ≥20% With Tirzepatide In People With Overweight Or Obesity In SURMOUNT-1
por: Srinath, Reshmi, et al.
Publicado: (2023)

SAT-593 Sex-Specific Modifications in MicroRNAs Contained in Exosomes of Astrocytes in Response to Palmitic Acid
por: Chowen, Julie Ann, et al.
Publicado: (2020)

Fatty Acids Modify the MicroRNA Content of Exosomes Released by Hypothalamic Astrocytes and the Response of POMC Neurons to These Exosomes
por: Collado-Pérez, Roberto, et al.
Publicado: (2021)

LBODP109 Astrocytes Affect The Metabolism Of Proopiomelanocortin (pomc) Neurons Through The Release Of Exosomes That Are Modified In A Fatty Acid Specific Manner
por: Collado-Pérez, Roberto, et al.
Publicado: (2022)

MON-111 Amenorrhea In Exercising Women Is Associated With A Greater Reduction In Post-prandial Ghrelin
por: Koltun, Kristen, et al.
Publicado: (2019)

MON-LB020 Compound H Causes a Sustained Reduction in Food Intake and Body Weight in Obese Cynomolgus
por: Hinke, Simon, et al.
Publicado: (2019)

Hepatic GH Receptor Signaling Directly Suppresses Hepatic Steatosis and De Novo Lipogenesis, Independent of Changes in Plasma IGF1 and Insulin
por: Vazquez Borrego, Maria del Carmen, et al.
Publicado: (2021)

SAT-LB022 Effects of Intermittent Versus Continuous Phentermine Therapy on Weight Reduction and Inflammatory Markers in Obese Non-diabetic Patients
por: Chai, Shu Teng, et al.
Publicado: (2019)

BIO89-100 Demonstrated Robust Reductions in Liver Fat and Liver Fat Volume (LFV) by MRI-PDFF, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH
por: Frias, Juan Pablo, et al.
Publicado: (2021)

SAT654 Regulation Of The Melanocortin-4 Receptor (mc4r) By Attractin Like Protein 1 (alp1)
por: Buscaglia, Paul, et al.
Publicado: (2023)

OR12-1 Leptin Is Transported across the Mouse Placenta
por: Park, Soyoung, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_krdnrjl0u0j2ve3p6diq7pgr83